To determine the prevalence of and identify risk factors for abnormal involuntary movements in a well-characterized community sample of neuroleptic-naive children and adolescents.
Method:
The Abnormal Involuntary Movement Scale (AIMS) was administered to 390 subjects aged 3–17 years who were in foster care. Additional instruments were used to assess intellect and behaviour problems.
Results:
A total 12.6% of subjects had at least 1 rating of “mild” movements on AIMS; these included 4.1% with at least 2 ratings of “mild” or 2 of “moderate” severity. Significant risk factors for movement disorder were younger age, lower IQ, and more severe behaviour problems. The abnormal movements were usually orofacial, and the affected subjects were generally unaware of these movements.
Conclusion:
The base prevalence of abnormal involuntary movements must be considered in children and adolescents assessed for medication in order to determine the true rate of motor side effects.
KaneJMJesteDVBarnesTRECaseyDEColeJO, Davis JM, and others. Tardive dyskinesia: A Task Force Report of the American Psychiatric Association. Washington (DC): American Psychiatric Association; 1992.
2.
KaneJMSmithJM. Tardive dyskinesia: Prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry1982;39:473–81.
BrandonSMcClellandHAProtheroeC. A study of facial dyskinesia, in a mental hospital population. Br J Psychiatry1971;118:171–84.
6.
CaseyDEHansenTE. Spontaneous dyskinesias. In: JesteDVWyattRJ, editors. Neuropsychiatric movement disorders. Washington (DC): American Psychiatric Press; 1984. p 67–95.
7.
DelwaidePJDesseillesM. Spontaneous buccolinguofacial dyskinesia in the elderly. Acta Neurol Scand1977;56:256–62.
8.
LiebermanJKaneJWoernerM. Prevalence of tardive dyskinesia in elderly samples. Psychopharmacol Bull1984;20:22–6.
9.
SutcherHDUnderwoodRBBeattyRA. Orofacial dyskinesia, a dental dimension. JAMA1971;216:1459–63.
10.
KollerWD. Edentulous orodyskinesia. Ann Neurol1982;13:97–9.
11.
CampbellMGregaDMGreenWHBennettWG. Neuroleptic-induced dyskinesias in children. Clin Neuropharmacol1983;6:207–22.
12.
CampbellMPerryRBennettWGSmallAMGreenWH, Grega D, and others. Long-term therapeutic efficacy and drug-related abnormal movements: A prospective study of haloperidol in autistic children. Psychopharmacol Bull1983;19:80–3.
13.
McAndrewJBCaseQTreffertDA. Effects of prolonged phenothiazine intake on psychotic and other hospitalized children. Journal of Autism and Child Schizophrenia1972;2:75–91.
14.
PaulsonGWRizviCACraneGE. Tardive dyskinesia as a possible sequel of long-term therapy with phenothiazines. Clin Pediatr1975;14:953–5.
15.
PolizosPEngelhardtD. Dyskinetic phenomena in children treated with psychotropic medications. Psychopharmacol Bull1978;14:65–8.
16.
PolizosPEngelhardtDMHoffmanSPWaizerJ. Neurological consequences of psychotropic drug withdrawal in schizophrenic children. Journal of Autism and Child Schizophrenia1973;3:247–53.
17.
RichardsonMAHauglandGCraigTJ. Neuroleptic use, Parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. Am J Psychiatry1991;148:1322–8.
18.
SilversteinFJohnstonM. Risks of neuroleptic drugs in children. J Child Neurol1987;2:41–3.
19.
TarsyDGranacherRBralowerM. Tardive dyskinesia in young adults. Am J Psychiatry1977;134:1032–4.
20.
WerryJSAmanMG. Methylphenidate and haloperidol in children: Effects on attention, memory and activity. Arch Gen Psychiatry1975;32:790–5.
21.
WerryJSAmanMGLamponE. Haloperidol and methlphenidate in hyperactive children. Acta Paedopsychiatrica1976;42:26–40.
22.
SchoolerNKaneJM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry1982;39:486–7.
23.
KhotVWyattRJ. Not all that moves is tardive dyskinesia. Am J Psychiatry1991;148:661–6.
24.
CampbellMAdamsPPerryRSpencerEKOverallJE. Tardive and withdrawal dyskinesia in autistic children: A prospective study. Psychopharmacol Bull1988;24:251–5.
25.
CampbellMAndersonLTCohenILPerryRSmallAM, Green WH, and others. Haloperidol in autistic children: Effects on learning, behavior, and abnormal involuntary movements. Psychopharmacol Bull1982;18:110–2.
26.
PerryRCampbellMGreenWHSmallAMTrillDie ML, Meiselas K, and others. Neuroleptic related dyskinesias in autistic children: A prospective study. Psychopharmacol Bull1985;21:140–3.
27.
GualtieriCTSchroederSRHicksREQuadeD. Tardive dyskinesia in young mentally retarded individuals. Arch Gen Psychiatry1986;43:335–40.
28.
GualtieriCTEvansR. Carbamazepine-induced tics. Dev Med Child Neurol1984;26:546–8.
29.
GualtieriCTBrenningSESchroederSRQuadeD. Tardive dyskinesia in mentally retarded children, adolescents and young adults: North Carolina and Michigan studies. Psychopharmacol Bull1982;18:62–5.
30.
MeiselasKSpencerEOberfieldRPeselowEDAngristBCampbellM. Differentiation of stereotypies from neuroleptic-related dyskinesias in autistic children. J Clin Psychopharmacol1989;9:207–9.
31.
GualtieriCTQuadeDHicksREMayoJPSchroederSR. Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. Am J Psychiatry1984;141:20–3.
32.
National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). Early Clinical Drug Evaluation Unit Intercom1975;4:3–6.
33.
DunnLM. Peabody Picture Vocabulary Test. Circle Pines (MN): American Guidance Service; 1981
34.
GageGENaumannTF. Correlation of the Peabody Picture Vocabulary Test and the Wechsler Intelligence Scale for Children. Journal of Educational Research1965;58:466–8.
35.
AchenbachTM. Manual for the Child Behavioral Checklist 4–18 and 1991 profile. Burlington: University of Vermont; 1991.
36.
CampbellMPalijM. Measurement of side effects including tardive dyskinesia. Psychopharmacol Bull1985;21:1063–75.
37.
MunetzMBenjaminS. How to examine patients using the abnormal involuntary movement scale. Hospital and Community Psychiatry1988;39:1172–7.
38.
GualtieriCTQuadeDHicksRE. 20 vignettes on VHS videotape, supported by NIMH grant 35339. In: Anonymous. Tardive dyskinesia: Differential diagnosis. Chapel Hill (NC): University of North Carolina; 1980.
39.
JesteDVWyattRJ. Understanding and treating tardive dyskinesia. New York: Guilford Press; 1982.
40.
ShroutPEFleissJL. Intraclass correlations: Uses in assessing rater reliability. Psychol Bull1979;86:420–8.
41.
BoncourGP. Les tics chez l'ecolier et leur interpretation. Le Progres Medical, 3rd Series1910;26:495–6.
42.
DeLongMRGeorgopoulosAPCrutcherMD. Cortico-basal ganglia relations and coding of motor performance. Exp Brain Res1983;7:30–40.
43.
Kellmer-PringleMLButlerNRDavieR. First report of national child development study. In: Anonymous. 11,000 seven-year-olds. London: National Bureau for Cooperation in Child Care; 1967. 185 p.
44.
ChouinardGRoss-ChouinardAAnnableLJonesBD. Extrapyramidal symptom rating scale [letter]. Can J Neurol Sci1980;7:233.
45.
DevinskyOGellerBD. Gilles de la Tourette's syndrome. In: JosephABYoungRR, editors. Movement disorders in neurology and neuropsychiatry. London: Blackwell Scientific Publicatons; 1992. p 471–8.
46.
YassaRJesteDV. Gender differences in tardive dyskinesia: A critical review of the literature. Schizophr Bull1992;18:701–15.
47.
ComingsDEHirnesJAComingsBG. An epidemiologic study of Tourette's syndrome in a single school district. J Clin Psychiatry1990;51:463–9.
48.
KurlanRWhitmoreDIrvineCMcDermottMPComoPG. Tourette's syndrome in a special education population: Preliminary findings. Neurology1993;43:A310.
49.
JesteDVCaligiuriMPPaulsenJSHeatonRKLacroJP, Harris MJ, and others. Risk of tardive dyskinesia in older patients: A prospective longitudinal study of 266 patients. Arch Gen Psychiatry1995;52:756–65.
50.
DencklaMBBemporadJRMackayMC. Tics following methylphenidate administration. JAMA1976;235:1349–51.
51.
KurlanR. Hypothesis II: Tourette's syndrome is part of a clinical spectrum that includes normal brain development. Arch Neurol1994;51:1145–50.
